Same-day Long-acting Reversible Contraception for Medication Abortion
Status:
Completed
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
Contraception after abortion is an important public health issue, as women who have an
abortion are at high risk for additional unintended pregnancy. In the context of first
trimester medical abortion, the standard of care is to administer long-acting reversible
contraception, including the etonogestrel implant (Implanon) and depot medroxyprogesterone
acetate (DMPA), at a follow-up appointment after the abortion.
The investigators plan to conduct a prospective observational pilot study to evaluate the
satisfaction of subjects who have selected either the contraceptive implant or DMPA given on
the first day of medical abortion, as opposed to at a follow-up appointment. The
investigators will also assess the continuation of DMPA and Implanon at 3, 6, 9, and 12
months after the initial date of administration. In addition, the investigators will assess
the total days of bleeding after the abortion, follow-up rate for evaluation of completion of
medical abortion, and efficacy of medical abortion.
A total of 40 participants will be recruited, 20 who choose Implanon and 20 who choose DMPA.
They will be asked to fill out questionnaires during the course of the study, and will be
followed for one year. The study duration including data analysis will be two years.